Fresenius SE & Co KGaA (FRE.DE) Akcija Цена
Fresenius SE & Co KGaA Цена
Prihod je rastao 4,0 % godišnje u poslednjih 19 godina na 22,87 Млрд EUR. Zarada po akciji rasla je 6,2 % godišnje u poslednjih 19 godina. neto marža kompanije Fresenius SE & Co KGaA sada iznosi 5,5 %, uglavnom stabilna sa 4,9 % pre nekoliko godina. Fresenius SE & Co KGaA trenutno nudi dividendni prinos od oko 2,05 %. Odnos isplate je oko 45 % dobiti. Dividenda je rasla 10,0 % godišnje u poslednjih 19 godina. Medijana analitičke ciljane cene je 57,12 EUR, odnosno iznad trenutnu cenu za 16,9 %. Od 23 analitičara 21 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije Fresenius SE & Co KGaA
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
Fresenius SE & Co KGaA poslovni model i analiza akcije
Često postavljana pitanja o akciji Fresenius SE & Co KGaA
Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.
Fresenius SE is primarily active in the healthcare industry.
The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.
Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.
Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.
Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.
Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 56,38 EUR za akciju Fresenius SE & Co KGaA (medijana: 57,12 EUR), što znači +15,6 % u odnosu na poslednju cenu. Konsenzus se zasniva na 23 ocena.
23 analitičara trenutno ocenjuje akciju Fresenius SE & Co KGaA: 21 preporučuje kupovinu, 2 držanje i 0 prodaju. Za 2026 analitičari očekuju da Fresenius SE & Co KGaA ostvari prihod 23,71 Млрд EUR i zaradu po akciji 3,63 EUR.
Akcija Fresenius SE & Co KGaA (FRE.DE) kotira na 10 berze, uključujući: London (0OO9.L), SIX (Zürich) (FREEUR.SW), XETRA (FRE.DE), Frankfurt (FRE.F), München (FRE.MU), Düsseldorf (FRE.DU), Hamburg (FRE.HM), Wien (FRE.VI).
Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.
očekivana prihod od Fresenius SE & Co KGaA je 23,71 Млрд EUR. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od Fresenius SE & Co KGaA je 2,05 Млрд EUR. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za Fresenius SE & Co KGaA je trenutno 13,45. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Fresenius SE & Co KGaA.
Odnos cene i prihoda (KUV) za Fresenius SE & Co KGaA je trenutno 1,16. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Fresenius SE & Co KGaA.
Eulpool score kvaliteta za Fresenius SE & Co KGaA je 2/10.
ISIN za Fresenius SE & Co KGaA je DE0005785604. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
WKN za Fresenius SE & Co KGaA je 578560. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.
Ticker za Fresenius SE & Co KGaA je FRE.DE. Simbol tikera se koristi za trgovinu akcijama Fresenius SE & Co KGaA na berzanskom tržištu.
Fresenius SE & Co KGaA акција
Fresenius SE & Co KGaA Peer grupa
Fresenius SE & Co KGaA Тикер
Fresenius SE & Co KGaA FIGI
Sve ključne metrke i detaljne analize Fresenius SE & Co KGaA u dubinskoj analizi
Naša analiza akcija za akciju Fresenius SE & Co KGaA uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Fresenius SE & Co KGaA. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: